NILOTINIB

Background Information:

A tyrosine kinase inhibitor (TKI) specifically targeting Bcr-Abl— the
definitive causative abnormality in CML—and its mutant forms, and is
significantly more selective and potent inhibitor of Bcr-Abl than
imatinib.

Reference:

1. Harmon B, Campbell N, Ratner L. Role of Abl Kinase and the Wave2
Signaling Complex in HIV-1 Entry at a Post-Hemifusion Step. PLoS Pathog.
2010 Jun 17;6(6):e1000956. PubMed PMID: 20585556.
2. Haubeiss S, Schmid JO, Muerdter TE, Sonnenberg M, Friedel G, van der
Kuip H, Aulitzky WE. Dasatinib reverses Cancer-associated Fibroblasts
(CAFs) from primary Lung Carcinomas to a Phenotype comparable to that of
normal Fibroblasts. Mol Cancer. 2010 Jun 27;9(1):168.
3. Koren-Michowitz M, le Coutre P, Duyster J, Scheid C, Panayiotidis P,
Prejzner W, Rowe JM, Schwarz M, Goldschmidt N, Nagler A. Activity and
tolerability of nilotinib: a retrospective multicenter analysis of
chronic myeloid leukemia patients who are imatinib resistant or
intolerant. Cancer. 2010 Jun 22. [Epub ahead of print] PubMed PMID:
20572041.

APIM050205: NILOTINIB

CAS No.: 641571-10-0.
Molecular Formula: C₂₈H₂₂F₃N₇O.
Molecular Weight: 529.5.
Purity: >99% (HPLC).
QC: HPLC, ¹HNMR, and Elemental Analysis Report.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.